Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables
Abstract
Use of genomic assays to determine distant recurrence risk in patients with early stage breast cancer has expanded and is now included in the American Joint Committee on Cancer staging manual. Algorithmic alternatives using standard clinical and pathology information may provide equivalent benefit in settings where genomic tests, such as OncotypeDx, are unavailable. We developed an artificial neural network (ANN) model to nonlinearly estimate risk of distant cancer recurrence. In addition to clinical and pathological variables, we enhanced our model using intraoperatively determined global mammographic breast density (MBD) and local breast density (LBD). LBD was measured with optical spectral imaging capable of sensing regional concentrations of tissue constituents. A cohort of 56 ER+ patients with an OncotypeDx score was evaluated. We demonstrated that combining MBD/LBD measurements with clinical and pathological variables improves distant recurrence risk prediction accuracy, with high correlation (r = 0.98) to the OncotypeDx recurrence score.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 03, 2020
- Source ID
- 10.1002/jbio.201960235
Entities
People
- Amanda Schulman
- Brandon S. Nichols
- Erika Chelales
- Jennifer Gallagher
- Joseph Geradts
- Josephine Harter
- Lee G. Wilke
- Nimmi Ramanujam
- Paul K Marcom
- Rachel A. Greenup
- Roujia Wang
Organizations
- Duke University
- National Institutes of Health
- National Science Foundation
- United States Department of Defense
- University of Wisconsin–Madison